RIGL Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company. It discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.

As of 07/01/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/05/2001
Outstanding shares:  172,052,224
Average volume:  13,254,888
Market cap:   $177,213,791
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      2833936
Valuation   (See tab for details)
PE ratio:   -2.29
PB ratio:   28.25
PS ratio:   2.09
Return on equity:   -1,248.29%
Net income %:   -99.89%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy